An observational study in Sarcoidosis, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Duke University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Sarcoidosis with a site in United States — 23 open to participants now, 25 under way, 3 of them phase 3. Sarcoidosis · United States.
Among the 115 studies in Sarcoidosis with a site in United States, this one has the largest planned enrollment of the 46 observational ones that give a count, is the only one that started in 2002, is one of 46 observational ones, reaches primary completion later than 22 of the 24 other live ones, and was the 40th registered.
271 studies on the registry are indexed under Sarcoidosis; 51 are open to participants now.
Browse Sarcoidosis studies →23 of the 115 studies in Sarcoidosis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18–85
The Cleveland Clinic · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+
Priovant Therapeutics, Inc. · Sites in United States, Australia, United Kingdom
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Sarcoidosis studies recruiting now, 30 (73%) set no upper age limit and 1 (2%) stops at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 37 · Phase 3 10 · Phase 4 12
First in 1978; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 27,000 is above the median of 130 across 109 observational studies indexed under Sarcoidosis.
Median enrollment 16 across the 69 interventional studies, 200 across the 46 observational. Of the 73 that completed or were terminated, 30 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 115 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 4 studies filed under Sarcoidosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Sarcoidosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03593759Phase 3Ottawa Heart Institute Research CorporationCardiac Sarcoidosis Randomized Trial | 2026-12 |
| NCT03621553University of Texas Southwestern Medical CenterVitamin D Homeostasis in Sarcoidosis | 2026-12 |
| NCT07159074Duke UniversityRepurposing Tilmanocept for Cardiac Sarcoidosis | 2026-12-01 |
| NCT05171478Johns Hopkins UniversityFull-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens | 2026-12-08 |
| NCT06510894University of PennsylvaniaDiagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 115 studies in Sarcoidosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to identify findings on cardiovascular MR imaging (CMR) that are specific to various cardiac or vascular disorders in patients undergoing routine CMR scans.
The objectives of this study are to 1) compare the information on your CMR scan to other clinical tests that you have undergone; and 2) determine whether the results of the CMR scan are predictive of future events related to heart or circulatory problems..
The criteria were revised on the registry on Oct 16, 2026. See what changed
Adults referred for routine CMR scans
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
cardiac mortality
Time frame: > 1year
arrhythmic death
Time frame: > 1year
Pulmonary mortality
only in subset of patients with pulmonary sarcoidosis
Time frame: > 1year
all-cause mortality
Time frame: > 1year
arrhythmic events
Time frame: > 1year
Pulmonary Transplant
Time frame: > 1 year
Cardiac Transplant
Time frame: > 1 year
PPM placement/high grade AV block
Time frame: > 1 year
Started Sep 2002 (actual). Primary completion is estimated for Jun 2032, 357 months after the start.
Of 59 non-industry observational studies under Sarcoidosis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 111. This study's planned 357 months is above that.
Counting every sponsor, half of 59 studies reached it within 49 months; a quarter within 20 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.